OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Borrello Sheds Light on the Multiple Myeloma Treatment Paradigm

October 31st 2019

Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.

Dr. Powles on Design and Findings of the BISCAY Trial in Platinum-Refractory Urothelial Cancer

October 31st 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Dr. Gadgeel on the Results of the BFAST Trial in ALK+ Lung Cancer

October 31st 2019

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the results of the phase II/III BFAST trial in patients with ALK-positive lung cancer.

Dr. Saba on Anticipated Research in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

Dr. Eward on FDA Approval of Pexidartinib in TGCT

October 30th 2019

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Dr. Cristofanilli on Aromatase Inhibitor Adverse Events in Breast Cancer

October 30th 2019

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

October 30th 2019

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Dr. Burns on Identifying Genetic Alterations in Lung Cancer

October 30th 2019

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.

Dr. Pennell on the Underutilization of Genetic Testing in Lung Cancer

October 30th 2019

Nathan A. Pennell, MD, PhD, discusses the underutilization of genetic testing in lung cancer.

Dr. Singh on Novel Therapies in Advanced Urothelial Cancer

October 29th 2019

Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.

Dr. Patel on Immunotherapy Landscape of Stage IV NSCLC

October 29th 2019

Jyoti D. Patel, MD, discusses current immunotherapy options in stage IV non–small cell lung cancer.

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in Myeloma

October 29th 2019

Simon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.

Dr. Stadtmauer Discusses Promising Targets in Multiple Myeloma

October 29th 2019

Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, Penn Medicine, University of Pennsylvania, discusses promising targets in multiple myeloma.

Dr. Robson Discusses the Driving Force Behind Biosimilar Use in Oncology

October 29th 2019

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

October 29th 2019

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

Dr. Segal on Next-Generation Sequencing for Lung Cancer

October 28th 2019

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

Targeting Wnt in BRAF-Mutant Colorectal Cancer

October 28th 2019

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Dr. Choi on Using Low-Dose CT Scans to Screen for Lung Cancer

October 26th 2019

Humberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRC

October 26th 2019

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer

October 26th 2019

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.